

**1st World Consensus Conference on BIA-ALCL  
“Present stage and future perspectives”**

**6 October 2019, Rome Italy**

**Presidents:** *F. Santanelli di Pompeo, M.W. Clemens*

*European Association of Plastic Surgeons (EURAPS), American Association of Plastic Surgeons (AAPS), American Society of Plastic Surgeons (ASPS), European Society of Plastic Reconstructive Surgery (ESPRAS), European Association of Societies of Aesthetic Plastic Surgery (EASAPS), International Confederation of Plastic Surgery Societies (ICOPLAST), Ibero-Latino-American Federation of Plastic Surgery (FILACP), Society of Plastic, Reconstructive and Aesthetic Surgery (SICPRE), Italian Association of Aesthetic Plastic Surgery (AICPE).*

**PRELIMINARY PROGRAM**

**6 October 2019**

- 08.00 Registration.
- 08.20 Welcome and opening. *F. Santanelli di Pompeo, Mark Clemens*
- 08.30 Key concepts on an uncommon and emerging malignancy - *M.W. Clemens*
- 09.00 A critical review of literature - *F. Santanelli di Pompeo*

**Correct Diagnosis, Data Collection and Analysis**

**Moderators:** *R. Van der Hulst, H. Rakhorst*

- 09.30 Histopathology and staging - *R. Miranda*
- 09.50 Epidemiology of the Netherlands and lesson from national registry tracking - *D. De Jong*
- 10.10 The essential role of breast implant registries to track BIA-ALCL in reconstructive and aesthetic surgery - *B. Stark*
- 10.30 Success and outcomes from the Netherlands device registry, setting the path to global device tracking  
*H. Rakhorst*
- 10.50 FILACP actions for data collection and implementation of diagnostic and treatment protocols in BIA-ALCL - *M. Del Mar Vaquero*
- 11.00 Exploring surgeon responsibility, an institutional experience notifying patients at risk - *D. MacKay*
- 11.20 Discussion
  
- 11.40 Coffee break

**Etiopathogenetic Hypothesis of BIA-ALCL**

**Moderators:** *A. Di Napoli, D. Hammond*

- 12.10 Chronic inflammation, the common trigger for lymphoma-genesis - *M. Sorotos*
- 12.30 Genetic background and predisposition - *A. Di Napoli*
- 12.50 Pathogenesis from the cell origin, what biomarkers reveal - *S. Turner*
- 13.10 The evidence for a biofilm derived endotoxin as disease trigger (teleconference from Brisbane  
h. 20.50) *A. Deva*
- 13.30 The potential role of particulates in the etiology of ALCL - *D. Hammond*
- 13.50 Discussion
  
- 14.10 Lunch

**Authorities**

15.00

**Clinical changes into actual and future practice**

**Moderator:** *D. Mackay, M. Hamdi*

- 15.20 Weighing risk versus benefit, the relevance and data of polyurethane cover implants  
*M. Hamdi*
- 15.40 Must we change our clinical approach to the use of breast implants, and what's next?  
*J. Saboye*
- 16.00 BIA-ALCL: what is the actual risk with macro-textured implants and how it has changed my  
practice - *P. Cordeiro*
- 16.20 Optimizing clinical approach to chronic seroma vs BIA-ALCL: experience in Mexico and Latin  
America- *G. Ramos-Gallardo*
- 16.40 Practice evolution in Canada, the influence of regulatory bodies - *J.E. Lipa*
- 17.00 Discussion
- 
- 17.20 Coffee break

**Perspective on the future of Breast Implant Technology**

**Moderators:** *F. Santanelli di Pompeo, M.W. Clemens*

- 17.50 *C. Brotherston, J. Canady, JJ Chaçon Quiros*
- 
- 18.50 Adjournment - *F. Santanelli di Pompeo, M.W. Clemens*